• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Cytokinetics Incorporated

    5/7/25 10:37:54 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYTK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    CYTOKINETICS INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    23282W605

    (CUSIP Number)


    04/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    23282W605


    1Names of Reporting Persons

    T. Rowe Price Investment Management, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MARYLAND
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    13,189,894.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    13,420,144.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    13,420,144.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.3 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CYTOKINETICS INC
    (b)Address of issuer's principal executive offices:

    350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
    Item 2. 
    (a)Name of person filing:

    T. Rowe Price Investment Management, Inc.
    (b)Address or principal business office or, if none, residence:

    1307 Point Street, Baltimore, MD 21231
    (c)Citizenship:

    Maryland
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    23282W605
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    13420144
    (b)Percent of class:

    11.3  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    13189894

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    13420144

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    T. Rowe Price Investment Management, Inc.
     
    Signature:Ellen York
    Name/Title:Vice President
    Date:05/07/2025
    Get the next $CYTK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYTK

    DatePrice TargetRatingAnalyst
    4/24/2025$55.00Overweight
    Barclays
    2/7/2025$86.00Buy
    Citigroup
    1/22/2025$80.00Buy
    Stifel
    11/8/2024$80.00Outperform
    RBC Capital Mkts
    8/13/2024$85.00 → $60.00Buy → Neutral
    Goldman
    1/24/2024$61.00 → $92.00Buy → Neutral
    UBS
    1/5/2024$60.00 → $90.00Overweight → Equal-Weight
    Morgan Stanley
    11/9/2023$50.00Buy
    Goldman
    More analyst ratings

    $CYTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP Research & Development Malik Fady Ibraham exercised 2,000 shares at a strike of $10.60 and sold $70,020 worth of shares (2,000 units at $35.01) (SEC Form 4)

      4 - CYTOKINETICS INC (0001061983) (Issuer)

      5/6/25 4:37:08 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Commercial Officer Callos Andrew sold $146,793 worth of shares (4,002 units at $36.68), decreasing direct ownership by 6% to 60,687 units (SEC Form 4)

      4 - CYTOKINETICS INC (0001061983) (Issuer)

      5/5/25 6:21:57 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Blum Robert I sold $204,800 worth of shares (5,000 units at $40.96), decreasing direct ownership by 1% to 417,629 units (SEC Form 4)

      4 - CYTOKINETICS INC (0001061983) (Issuer)

      4/29/25 4:33:42 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cytokinetics Incorporated

      SC 13G - CYTOKINETICS INC (0001061983) (Subject)

      11/14/24 1:28:31 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

      SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

      11/12/24 2:21:36 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

      SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

      11/12/24 9:55:17 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

      SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025. Late Breaking Science Presentations Title: Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild SymptomsPresenter: Iacopo Olivotto, M.D., Professor of Cardiology at the University of Florence, Head of Cardiology at Meyer Children's Hospital, Florence, ItalyDate: May 17, 2025Topic: Chronic Heart FailureSe

      5/8/25 4:00:00 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cytokinetics to Hold Annual Meeting of Stockholders

      SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 14, 2025 at 10:00 AM Pacific Time at the Company's headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present a company update. Stockholders of record at the close of business on March 24, 2025 are entitled to vote at Cytokinetics' Annual Meeting of Stockholders or to attend in person and submit questions to management. Stockholders wishing to vote m

      5/7/25 4:00:00 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

      PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the first quarter of 2025. "In the first quarter, we made progress towards commercial readiness and advanced our specialty cardiology pipeline," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "Recently, our PDUFA date for aficamte

      5/6/25 4:00:00 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Cytokinetics Incorporated

      SCHEDULE 13G - CYTOKINETICS INC (0001061983) (Subject)

      5/7/25 10:37:54 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cytokinetics Incorporated

      10-Q - CYTOKINETICS INC (0001061983) (Filer)

      5/6/25 4:30:33 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cytokinetics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CYTOKINETICS INC (0001061983) (Filer)

      5/6/25 4:05:10 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on Cytokinetics with a new price target

      Barclays initiated coverage of Cytokinetics with a rating of Overweight and set a new price target of $55.00

      4/24/25 7:43:15 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Cytokinetics with a new price target

      Citigroup initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $86.00

      2/7/25 8:37:05 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Cytokinetics with a new price target

      Stifel initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $80.00

      1/22/25 7:34:24 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    Financials

    Live finance-specific insights

    See more
    • Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

      PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the first quarter of 2025. "In the first quarter, we made progress towards commercial readiness and advanced our specialty cardiology pipeline," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "Recently, our PDUFA date for aficamte

      5/6/25 4:00:00 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cytokinetics to Announce First Quarter Results on May 6, 2025

      SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report first quarter results on May 6, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cytokinetics Q1 2025 Earnings Confe

      4/22/25 3:59:59 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

      Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and China Topline Results from MAPLE-HCM Expected in Q2 2025 Company Provides 2025 Financial Guidance; ~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2024 SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the fourth quarter and full year of 2024. The company also provided full year 2025 financial guidance. "The fourth quarter of 2024 capped off

      2/27/25 4:00:00 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    Leadership Updates

    Live Leadership Updates

    See more
    • Cytokinetics Names Robert E. Landry to Board of Directors

      Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years. "We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medici

      2/11/25 7:30:00 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Super Micro Computer and Deckers Outdoor Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 1, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed

      3/1/24 6:47:00 PM ET
      $AIT
      $AL
      $APPS
      $ARCH
      Industrial Specialties
      Consumer Discretionary
      Diversified Commercial Services
      Multi-Sector Companies